These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1109 related items for PubMed ID: 27417017

  • 1. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA.
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [Abstract] [Full Text] [Related]

  • 2. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
    Eichenfield LF, Yosipovitch G, Stein Gold LF, Kalabis M, Zang C, Vlahos B, Sanders P, Myers DE, Bushmakin AG, Cappelleri JC, Olivadoti M, Paller AS.
    Pediatr Dermatol; 2020 Nov; 37(6):1030-1037. PubMed ID: 32981097
    [Abstract] [Full Text] [Related]

  • 3. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
    Ahmed A, Solman L, Williams HC.
    Br J Dermatol; 2018 Mar; 178(3):659-662. PubMed ID: 29205284
    [Abstract] [Full Text] [Related]

  • 4. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, Sanders P, Vlahos B, Zang C, Lan J, Werth J.
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [Abstract] [Full Text] [Related]

  • 5. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
    Murrell DF, Gebauer K, Spelman L, Zane LT.
    J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
    [Abstract] [Full Text] [Related]

  • 6. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
    Luger TA, Hebert AA, Zaenglein AL, Silverberg JI, Tan H, Ports WC, Zielinski MA.
    Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
    [Abstract] [Full Text] [Related]

  • 7. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
    Stein Gold LF, Spelman L, Spellman MC, Hughes MH, Zane LT.
    J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
    Spergel JM, Blaiss MS, Lio P, Kessel A, Cantrell WC, Takiya L, Werth JL, O'Connell MA, Zang C, Cork MJ.
    Allergy Asthma Proc; 2021 Sep 01; 42(5):425-431. PubMed ID: 34474712
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
    Callender VD, Alexis AF, Stein Gold LF, Lebwohl MG, Paller AS, Desai SR, Tan H, Ports WC, Zielinski MA, Tallman AM.
    Am J Clin Dermatol; 2019 Oct 01; 20(5):711-723. PubMed ID: 31264114
    [Abstract] [Full Text] [Related]

  • 11. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
    Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, Ports WC, Purohit V, Takiya L, Werth JL, Zang C, Vlahos B, CARE 1 Investigators.
    Am J Clin Dermatol; 2020 Apr 01; 21(2):275-284. PubMed ID: 32212104
    [Abstract] [Full Text] [Related]

  • 12. Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.
    Stein Gold LF, Takiya L, Zang C, Sanders P, Feldman SR.
    J Drugs Dermatol; 2020 Jun 01; 19(6):619-624. PubMed ID: 32574023
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
    Eichenfield LF, Call RS, Forsha DW, Fowler J, Hebert AA, Spellman M, Stein Gold LF, Van Syoc M, Zane LT, Tschen E.
    J Am Acad Dermatol; 2017 Oct 01; 77(4):641-649.e5. PubMed ID: 28823881
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
    Tom WL, Van Syoc M, Chanda S, Zane LT.
    Pediatr Dermatol; 2016 Oct 01; 33(2):150-9. PubMed ID: 26777394
    [Abstract] [Full Text] [Related]

  • 15. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
    Ständer S, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Tom WL, Ports WC, Zielinski MA, Tallman AM, Tan H, Gerber RA.
    J Eur Acad Dermatol Venereol; 2019 Sep 01; 33(9):1742-1746. PubMed ID: 31132182
    [Abstract] [Full Text] [Related]

  • 16. Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis.
    Stein Gold LF, Tom WL, Shi V, Sanders P, Zang C, Vlahos B, Cha A.
    Dermatitis; 2024 Sep 01; 35(1):84-91. PubMed ID: 38206678
    [Abstract] [Full Text] [Related]

  • 17. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis.
    Fujita K, Yagi M, Moriwaki S, Yoshida M, Graham D.
    J Dermatol; 2021 Nov 01; 48(11):1640-1651. PubMed ID: 34435694
    [Abstract] [Full Text] [Related]

  • 18. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM.
    Am J Clin Dermatol; 2017 Dec 01; 18(6):837-843. PubMed ID: 29076116
    [Abstract] [Full Text] [Related]

  • 19. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
    Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, Purohit VS, Zielinski MA, Vlahos B, Estrada YD, Saint-Cyr Proulx E, Ports WC, Guttman-Yassky E.
    J Allergy Clin Immunol; 2019 Nov 01; 144(5):1274-1289. PubMed ID: 31419544
    [Abstract] [Full Text] [Related]

  • 20. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
    Yosipovitch G, Gold LF, Lebwohl MG, Silverberg JI, Tallman AM, Zane LT.
    Acta Derm Venereol; 2018 Apr 27; 98(5):484-489. PubMed ID: 29363715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.